Medvedchuk negotiates transferring technology for the Sputnik V vaccine production to Ukraine
The production of the Sputnik V COVID-19 vaccine, developed by the Russian National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya, can be established in Ukraine at the Bіolik enterprise in Kharkiv. This was subject of arrangement reached in Moscow between Viktor Medvedchuk, chair of the political council of the Opposition Platform – For Life party, Oleksandr Gintsburg, director of the N.F. Gamaleya Research Center and Kyryl Dmytriyev, CEO of the Russian Direct Investment Fund (RDIF).
Particularly, representatives of the Russian side committed to conclude an agreement on the transfer of technology, as well as on the transfer of raw materials – a cell line for the production of vaccines in Ukraine. This became possible thanks to the activities of the joint Ukrainian-Russian working group, established following the meeting of Russian President Volodymyr Putin with Viktor Medvedchuk on October 6 this year.
“I used to receive thousands of appeals, same is with the political force that I represent, including from scientific, medical institutions, public organizations. They all limited to the following: if the Ukrainian government does not agree to purchase the Sputnik V vaccine, then probably we can help ensure that this vaccine is produced on the territory of Ukraine,” Viktor Medvedchuk explained. “Finally, we created a working group with representatives of the Gamaleya center and after a month of work we came up with a result that is significant for Ukraine. We are talking about the possibility of transferring technology for the production of vaccines to Ukraine, as well as the provision of raw materials in the form of a cell line and the ability to produce this vaccine at Ukrainian production facilities.”
On his part, Kyryl Dmytriyev confirmed that the Bіolik enterprise in Kharkiv meets all the necessary requirements. “This enterprise is very high-tech. We will apply for permission to start producing this vaccine in Ukraine this month and, accordingly, supplying it to foreign markets, such as Belarus,” he said. “Over time, if there is an appropriate permission from Ukraine, this vaccine can, definitely, also enter the Ukrainian markets.”
Oleksandr Gintsburg thanked Viktor Medvedchuk for his trust to the Sputnik V vaccine and assured that the institute headed by him has broad experience in transferring the technologies it has developed to other sites. “We will do things as quickly and efficiently as possible in order to transfer this technology, to train specialists at the site that you have selected on the territory of Ukraine. I guarantee you that we will transfer absolutely all the subtleties of the technological process so that the Ukrainian population has the opportunity to be protected from this infection in the nearest future,” the director of the N.F. Gamaleya Research Center outlined.
Viktor Medvedchuk also noted that the production of a vaccine against coronavirus, which is what all the leading countries of the world are doing today, is possible in Ukraine very shortly. The production facilities have been found, they meet all the standards for the application of technology for the production of vaccines. However, the further fate of this issue depends on the Ukrainian government.
“Naturally, the next question goes to the Ukrainian government. Everything will depend on Kyiv’s desire to provide Ukrainian citizens with effective protection in the fight against the plague of the 21st century, which, unfortunately, is fairly called the coronavirus,” he said. “We need to do everything necessary to protect our people, the citizens of Ukraine, despite the specific attitude of our government,” Viktor Medvedchuk summed up.
To recall, on October 6, Viktor Medvedchuk met with President of the Russian Federation Volodymyr Putin to raise the issue of the possibility of supplying the Sputnik V vaccine developed by the National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya, to the territory of Ukraine to protect the life and health of Ukrainian citizens. In early November, Viktor Medvedchuk had another meeting with the President of the Russian Federation, where he voiced a request to produce the Sputnik V vaccine (with a confirmed efficiency of 95%) in Ukraine.